Therapy of chronic lymphocytic leukaemia

被引：22
|
作者：
Hallek, Michael [1 ]
机构：
[1] Univ Cologne, Innere Med Klin 1, Ctr Integrated Oncol Koln Bonn, D-50924 Cologne, Germany
来源：
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY | 2010年 / 23卷 / 01期
关键词：
therapy; antibody; purin analogue; rituximab; fitness; first-line second-line; allogeneic stem cell transplantation; CLL; FLUDARABINE PLUS CYCLOPHOSPHAMIDE; PHASE-III TRIAL; PREVIOUSLY UNTREATED PATIENTS; PROGRESSION-FREE SURVIVAL; RESIDUAL DISEASE; 1ST-LINE THERAPY; CLINICAL-EFFICACY; 1ST REMISSION; RITUXIMAB; ALEMTUZUMAB;
D O I：
10.1016/j.beha.2009.12.002
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Rapid progress has been achieved recently in the management of chronic lymphocytic leukaemia (CLL). New insights into the molecular pathology of CLL have generated a plethora of biological markers that predict the prognosis and influence therapeutic decisions. Moreover, fludarabine, bendamustine and two monoclonal antibodies, alemtuzumab and rituximab, have been approved by European and/or American regulatory agencies. Additional monoclonal antibodies targeting CD20, CD23, CD37, CD38 or CD40, as well as drugs designed to interfere with proteins regulating the cell cycle, apoptotic machinery or leukaemic microenvironment (e.g., flavopiridol, oblimersen, ABT-263 or lenalidomide) are investigated in clinical trials. An increased experience with reduced-intensity allogeneic progenitor cell transplantation allows offering this option to physically fit patients. This review attempts to summarise the current use of these different modalities in CLL therapy. (C) 2010 Published by Elsevier Ltd.
引用
收藏
页码：85 / 96
页数：12
相关论文
共 50 条
  • [21] Chronic lymphocytic leukaemia
    Hallek, M.
    [J]. EJC SUPPLEMENTS, 2010, 8 (04): : 6 - 6
  • [22] Chronic lymphocytic leukaemia
    [J]. Nature Reviews Disease Primers, 3 (1)
  • [23] Chronic lymphocytic leukaemia
    Hallek, Michael
    Shanafelt, Tait D.
    Eichhorst, Barbara
    [J]. LANCET, 2018, 391 (10129): : 1524 - 1537
  • [24] Chronic Lymphocytic Leukaemia
    Boelens, Jerina
    Lust, Sofie
    Vanhoecke, Barbara
    Offner, Fritz
    [J]. ANTICANCER RESEARCH, 2009, 29 (02) : 605 - 615
  • [25] Chronic lymphocytic leukaemia
    Oscier, D
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1999, 105 : 1 - 3
  • [26] Therapy of Chronic Lymphocytic Leukaemia with Purine Nucleoside AnaloguesFacts and Controversies
    Tadeusz Robak
    [J]. Drugs & Aging, 2005, 22 : 983 - 1012
  • [27] Alemtuzumab based therapy in high risk chronic lymphocytic leukaemia
    Hewamana, S.
    Kalkur, P.
    Swansbury, J.
    Morilla, R.
    Morilla, A.
    Kabir, M.
    Morgan, S.
    Whiteman, L.
    Chau, I.
    Cunningham, D.
    Dearden, C.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 : 48 - 49
  • [28] Rituximab-containing therapy for chronic lymphocytic leukaemia Reply
    Hallek, M.
    Fink, A.
    Busch, R.
    Fischer, K.
    [J]. LANCET, 2011, 377 (9761): : 206 - 206
  • [29] Chronic lymphocytic leukaemia: current first-line therapy
    Carney, D. A.
    Mulligan, S. P.
    [J]. INTERNAL MEDICINE JOURNAL, 2009, 39 (01) : 44 - 48
  • [30] Molecular basis of pathogenesis, prognosis and therapy in chronic lymphocytic leukaemia
    Chen, Jiezhong
    McMillan, Nigel A. J.
    [J]. CANCER BIOLOGY & THERAPY, 2008, 7 (02) : 174 - 179
12345